Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Cetuximab

Aliases
C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140 (12 other aliases)

121 clinical trials

126 indications

Indication
Colorectal Cancer
Indication
Esophageal Adenocarcinoma
Indication
Esophageal Squamous Cell Carcinoma
Indication
Stomach Cancer
Indication
Hepatocellular Carcinoma
Indication
Gastrointestinal stromal tumor
Indication
Recurrent head and neck cancer
Indication
Metastatic Head and Neck Cancer
Indication
BRAF V600E
Indication
Pancreatic Ductal Adenocarcinoma
Indication
Squamous Cell Carcinoma of Head and Neck
Indication
Head and Neck Squamous Cell Carcinoma
Indication
Cancer
Indication
Squamous Cell Carcinoma of the Head and Neck
Indication
Advanced Solid Tumor
Indication
Metastatic Head-and-neck Squamous-cell Carcinoma
Indication
BRAF V600E-mutant Metastatic Colorectal Cancer
Indication
Head and Neck Cancer
Indication
Solid Tumors
Indication
KRAS p.G12C
Indication
Advanced Cancer
Indication
Metastatic Cancer
Indication
Malignant Neoplastic Disease
Indication
Small Intestinal Cancer
Indication
Appendiceal Cancer
Indication
Metastatic Melanoma
Indication
Metastatic Non-small Cell Lung Cancer
Indication
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Indication
Metastatic Solid Tumors
Indication
Solid Tumor
Indication
Breast Cancer
Indication
Elderly
Indication
Cutaneous Squamous Cell Carcinoma
Indication
Anal Squamous Cell Carcinoma
Indication
Cervical Cancer
Indication
Colorectal cancer
Indication
Head and Neck Squamous Cell Cancer
Indication
Head and Neck Neoplasms
Indication
NSCLC
Indication
Locally Advanced Solid Tumor
Indication
Metastatic Solid Tumor
Indication
Lung Cancer
Indication
Ovarian Cancer
Indication
Pancreatic Cancer
Indication
Gastric Esophageal Cancer
Indication
Colorectal Cancer Metastatic
Indication
Advanced or Metastatic Solid Tumors
Indication
Colorectal Cancer stage IV AJCC v8
Indication
Colon Cancer
Indication
Colon
Indication
Recurrent Non-Small Cell Lung Carcinoma
Indication
Stage IV Non-Small Cell Lung Cancer
Indication
Locally Advanced
Indication
cancer
Indication
Non-Small Cell Lung
Indication
Endometrial Neoplasms
Indication
Biliary Tract Neoplasms
Indication
Brain Cancer
Indication
Neck Cancer
Indication
HNSCC
Indication
Metastatic Lung Non-Small Cell Carcinoma
Indication
Recurrent Lung Non-Small Cell Carcinoma
Indication
Stage IV Lung Cancer
Indication
lung cancer
Indication
Surgery
Indication
Circulating Tumor Cell
Indication
MRD
Indication
Treatment Related Cancer
Indication
ERBB2 Gene Amplification
Indication
Rectal Adenocarcinoma
Indication
Recurrent Colorectal Cancer
Indication
Rectal Cancer
Indication
Stage IIIA Colon Cancer
Indication
Stage IIIA Rectal Cancer
Indication
Stage IV Colon Cancer AJCC v7
Indication
Rectal Cancer, Stage IVA (AJCC v7)
Indication
Thymoma
Indication
Thymic Carcinoma
Indication
Clinical Masaoka Stage II to IVA
Indication
BRAF
Indication
Colon Adenocarcinoma
Indication
Progressive Disease
Indication
Stage IIIA Colorectal Cancer AJCC v8
Indication
Colorectal Cancer, Stage IIIB
Indication
Stage IVA Colorectal Cancer AJCC v8
Indication
Stage IVB Colorectal Cancer AJCC v8
Indication
Stage IVC Colorectal Cancer AJCC v8
Indication
Stage III Colon Cancer
Indication
Rectal cancer
Indication
Stage IV Rectal Cancer
Indication
Squamous Cell Carcinoma of the Oropharynx
Indication
Larynx Squamous Cell Carcinoma
Indication
Oral Squamous Cell Carcinoma
Indication
Squamous Cell Carcinoma of the Hypopharynx
Indication
Squamous Cell Carcinoma of the Paranasal Sinus
Indication
Squamous Cell Carcinoma
Indication
Head and Neck Carcinoma
Indication
Chemotherapy Effect
Indication
Molecular Sequence Variation
Indication
Glioblastoma
Indication
Anaplastic Astrocytoma
Indication
Anaplastic Oligoastrocytoma
Indication
Glioma
Indication
Brain tumor
Indication
Brain Tumor
Indication
Recurrent
Indication
malignant
Indication
Metastatic Head and Neck Squamous Cell Cancer
Indication
Liver Metastases
Indication
Metastatic Head and Neck Squamous Cell Carcinoma
Indication
Pancreatic Ductal
Indication
KRAS wild type Allele
Indication
Metastatic Malignant Solid Neoplasm
Indication
Neoplasm
Indication
Chordoma
Indication
KRAS G12C Mutations
Indication
Skin Cancer
Indication
Locally Recurrent OCSCC
Indication
Hypopharyngeal Squamous Cell Carcinoma
Indication
Stage III Laryngeal Squamous Cell Carcinoma
Indication
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Indication
Laryngeal Squamous Cell Carcinoma
Indication
Oropharyngeal Squamous Cell Carcinoma AJCC v7
Indication
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Indication
Oropharyngeal Squamous Cell Carcinoma
Indication
EGFR Gene Overexpression
Clinical trial
A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of SOT101 in Combination With Cetuximab in Patients With RAS Wild-type Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-26
Clinical trial
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2019-02-25
Clinical trial
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Status: Active (not recruiting), Estimated PCD: 2023-12-19
Clinical trial
A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SIBP-03 Injection Combined With Cetuximab in Patients With Recurrent/Metastatic Advanced Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma)
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2023-07-21
Clinical trial
Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-14
Clinical trial
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
Status: Active (not recruiting), Estimated PCD: 2022-05-11
Clinical trial
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2019-02-11
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Status: Active (not recruiting), Estimated PCD: 2018-07-19
Clinical trial
Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)
Status: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2021-10-26
Clinical trial
A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-08-21
Clinical trial
A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2029-05-01
Clinical trial
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)
Status: Recruiting, Estimated PCD: 2026-11-10
Clinical trial
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
Status: Recruiting, Estimated PCD: 2025-01-06
Clinical trial
A Phase 1, Dose Escalation and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of BND-35 Administered Alone and in Combination With Nivolumab or With Cetuximab in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
Status: Recruiting, Estimated PCD: 2026-03-28
Clinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Status: Completed, Estimated PCD: 2021-02-10
Clinical trial
A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN
Status: Completed, Estimated PCD: 2018-07-19
Clinical trial
An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2023-03-28
Clinical trial
Encorafenib and Cetuximab in Patients With Metastatic, BRAFV600E-mutated, Colorectal Carcinoma: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Multicenter, Open-label, Parallel-group，Randomised, Phase IIb Trial of Efficacy and Safety of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI Versus Ametumumab or Cetuximab in Combination With FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2023-01-01
Clinical trial
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer
Status: Completed, Estimated PCD: 2017-05-15
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers
Status: Active (not recruiting), Estimated PCD: 2024-06-20
Clinical trial
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2013-02-05
Clinical trial
A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)
Status: Terminated, Estimated PCD: 2022-03-14
Clinical trial
An Open, Multicenter Phase II Clinical Study to Evaluate Safety and Efficacy of HLX208 (BRAF V600E Inhibitor) Combined With Cetuximab in Patients With Metastatic Colorectal Cancer (mCRC)
Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase Ib, Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Completed, Estimated PCD: 2015-11-06
Clinical trial
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
An Open-label, Multicenter, Phase Ib/III Study of Efficacy and Safety of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2023-08-30
Clinical trial
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab for Advanced and/or Metastatic Colorectal Cancer (CRC) and Advanced and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Not yet recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Completed, Estimated PCD: 2018-06-01
Clinical trial
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES
Status: Recruiting, Estimated PCD: 2026-04-19
Clinical trial
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
APK Mutant: A Single Arm Phase II Study of Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Status: Terminated, Estimated PCD: 2024-02-20
Clinical trial
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-29
Clinical trial
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2018-09-25
Clinical trial
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2024-03-11
Clinical trial
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-20
Clinical trial
A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line
Status: Active (not recruiting), Estimated PCD: 2025-08-15
Clinical trial
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
Status: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase 1 Trial of CTLA-4 Inhibition, With or Without Cetuximab, and in Combination With Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Are Anti-EGFR Monoclonal Antibodies the Magic Bullets That Remove Circulating EGFR+EpCAM+ Tumor Cells in Patients With Non-small Cell Lung Cancer
Status: Withdrawn, Estimated PCD: 2022-09-19
Clinical trial
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
Status: Not yet recruiting, Estimated PCD: 2027-01-18
Clinical trial
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA: an Open, Prospective, Phase II Study
Status: Recruiting, Estimated PCD: 2028-09-01
Clinical trial
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy in Pre-treated RAS/BRAF Wild Type Metastatic Colorectal Cancer Patients.
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Avelumab Added to FOLFIRI Plus Cetuximab Followed by Avelumab Maintenance in Patients With Previously Untreated RAS Wild-type Colorectal Cancer. The Phase II FIRE-6 Study
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2025-12-04
Clinical trial
A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Status: Completed, Estimated PCD: 2021-10-12
Clinical trial
A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2021-09-04
Clinical trial
Predictive Value of Other Oncogene Mutations for Anti-EGFR Monoclonal Antibodies Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer: Multicenter Randomized Phase III Trial
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2020-02-04
Clinical trial
An Open, Single-center, Phase II Trial of Cetuximab+Zimberelimab Combined With Platinum-containing Dual-agent Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 1 Study of Concurrent Cabozantinib and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design
Status: Recruiting, Estimated PCD: 2030-12-01
Clinical trial
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Status: Completed, Estimated PCD: 2020-06-08
Clinical trial
A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2015-09-29
Clinical trial
A Pilot Window of Opportunity Study of Imatinib in Combination With Cetuximab in Patients With Squamous Cell Carcinomas of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN
Status: Completed, Estimated PCD: 2018-09-11
Clinical trial
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
Status: Not yet recruiting, Estimated PCD: 2027-07-13
Clinical trial
Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2022-01-19
Clinical trial
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type Metastatic Colorectal Cancer: A Single-center, Prospective Phase Ib/II Study
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
A Phase II Trial of Cetuximab for Patients With Advanced or Metastatic Chordoma
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Status: Active (not recruiting), Estimated PCD: 2019-04-11
Clinical trial
Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
Status: Completed, Estimated PCD: 2022-09-06
Clinical trial
Bevacizumab Plus encoRAfenib-cetuximab in BRAF-V600E Mutated Metastatic Colorectal Cancer, a Phase II Study With a Safety lead-in Cohort, the BRAVE Trial
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase II Study Evaluating Holmium-166 TARE Followed by Maintenance Therapy in Liver Limited Unresectable Colorectal Cancer Patients After First-line Chemotherapy and Target Agents
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase III, Multicenter, Open-label, Randomized Study to Assess the Efficacy and Safety of Cetuximab Plus Capecitabine Versus Cetuximab as Maintenance Treatment Following First-line Induction Treatment With FOLFOX and Cetuximab in Chinese Patients With RAS and BRAF Wild-type Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase 2 Study to Evaluate the Efficacy of the Combination of Cemiplimab and Cetuximab Prior to Salvage Surgery in Patients With Locally Recurrent (Stage 3-5) OCSCC
Status: Not yet recruiting, Estimated PCD: 2025-05-15
Clinical trial
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Status: Recruiting, Estimated PCD: 2026-03-28
Clinical trial
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
Status: Completed, Estimated PCD: 2016-10-29
Clinical trial
Phase II Study of AVELUMAB and CETUXIMAB and Modified FOLFOXIRI as Initial Therapy for RAS Wild-type Unresectable Metastatic Colorectal Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-06-28
Clinical trial
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2002-01-01
Clinical trial
Phase I/II Trial of Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Accelerated Modulated Fractionation (SIB-IMRT) for the Treatment of Locally Advanced Squamous Cell Carcinoma From Head and Neck District
Status: Recruiting, Estimated PCD: 2018-12-01
Clinical trial
Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2009-07-01